Oruka Therapeutics NASDAQ:ORKA disclosed in a Form 4 filing that Arjun Agarwal, the company’s Senior Vice President of Finance, sold 395 shares of common stock on March 16, 2026. The shares changed hands at $41.30 apiece, producing a total transaction value of $16,313. According to the filing, the disposition was executed to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sale occurred while Oruka shares were trading close to their 52-week high of $42.41, following a pronounced 251% advance over the past year. After completing the transaction, Agarwal directly holds 18,863 shares of the company.
Separately, market data referenced in the filing notes a divergence of views on valuation. InvestingPro data cited alongside the disclosure suggests the shares may be overvalued at current prices. At the same time, the company’s balance sheet position is described as strong, with cash exceeding debt on the books.
Pipeline progress has been a focal point for recent analyst activity on Oruka. The company reported positive interim results from its Phase 1 trial of ORKA-002, data the company said indicates a substantially longer half-life for the molecule. That pharmacokinetic profile could permit less frequent dosing for indications such as psoriasis and hidradenitis suppurativa, according to the announcement.
Those clinical updates have prompted multiple brokerages to revise their valuations and ratings. Clear Street lifted its price target for Oruka from $46 to $71, while keeping a Buy rating. Stifel raised its price target to $72 and cited an accelerated timeline for ORKA-001 Phase 2 psoriasis data, which is now expected in the second quarter of 2026. BTIG reiterated a Buy rating with a $73 target and noted that enrollment for the ORKA-001 trial was completed in December 2025. UBS initiated coverage on Oruka with a Buy rating and a $50 price target, highlighting the company’s late-stage Phase III selective estrogen receptor degrader in metastatic cancer settings.
The combination of insider stock activity, valuation commentary, and forward-looking analyst actions frames the company’s current market narrative. The insider sale was characterized in the filing as a tax-driven transaction tied to restricted stock unit vesting, while multiple brokerages pointed to advancing clinical data and trial milestones as the basis for higher near-term price targets.
Investors and market participants will likely continue to monitor clinical readouts and analyst revisions, as well as any further insider activity, to gauge momentum and valuation dynamics for Oruka Therapeutics.